• Scotiabank maintains an "Outperform" rating for NYSE:TEVA, raising its price target from $35 to $40.
• TEVA reported a significant increase in fourth-quarter profit, driven by strong sales of branded drugs and a milestone payment.
• The stock's current price is $32.54, with a year-high of $33.43 and a low of $12.47, indicating volatility and growth potential.

Teva Pharmaceutical Industries, listed on the NYSE as TEVA, is a global leader in generic and specialty medicines. The company focuses on developing, producing, and marketing generic drugs and innovative pharmaceuticals. Teva competes with other pharmaceutical giants like Pfizer and Novartis. On January 29, 2026, Scotiabank maintained its "Outperform" rating for TEVA, with the stock priced at $32.64.

Scotiabank also raised its price target for Teva from $35 to $40, as highlighted by TheFly. This optimistic outlook aligns with Teva's recent financial performance. The company reported a significant increase in its fourth-quarter profit, driven by strong sales of branded drugs and a milestone payment for a late-stage study on treatments for ulcerative colitis and Crohn's disease.

Despite the positive outlook, TEVA's current stock price is $32.54, reflecting a decrease of 2.03% with a change of $0.68. Today, the stock has fluctuated between a low of $32.19 and a high of $33.43, which is also its highest price over the past year. The lowest price TEVA has reached in the past year is $12.47.

Teva's market capitalization stands at approximately $37.31 billion, indicating its substantial presence in the pharmaceutical industry. Today's trading volume for TEVA is 2,763,304 shares, reflecting active investor interest. The company's strong financial performance and Scotiabank's positive rating suggest potential growth opportunities for investors.